Associated Papers
Molecular determinants of HERG potassium channel blockade by domiphen bromide and benzethonium chloride.
Tang F et al.
Pflugers Archiv : European Journal of Physiology, 2025
Harnessing AlphaFold to reveal hERG channel conformational state secrets.
Ngo K et al.
Biorxiv : the Preprint Server for Biology, 2025
Stereoselective block of the hERG potassium channel by the Class Ia antiarrhythmic drug disopyramide.
Zhang Y et al.
Cellular and Molecular Life Sciences : Cmls, 2024
Multiplexed Assays of Variant Effect and Automated Patch-clamping Improve KCNH2-LQTS Variant Classification and Cardiac Event Risk Stratification.
O'Neill MJ et al.
Medrxiv : the Preprint Server for Health Sciences, 2024
Impacts of gene variants on drug effects-the foundation of genotype-guided pharmacologic therapy for long QT syndrome and short QT syndrome.
Zhao Z et al.
Ebiomedicine, 2024
Inhibition of the hERG Potassium Channel by a Methanesulphonate-Free E-4031 Analogue.
Helliwell MV et al.
Pharmaceuticals (basel, Switzerland), 2023
Identification of a novel pathogenic variant in KCNH2 in an Iranian family with long QT syndrome 2 by whole-exome sequencing.
Fazelifar AF et al.
Journal of Arrhythmia, 2023
Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls.
Walsh R et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2021
A structure-based computational workflow to predict liability and binding modes of small molecules to hERG.
Kalyaanamoorthy S et al.
Scientific Reports, 2020
The molecular determinants of R-roscovitine block of hERG channels.
Cernuda B et al.
Plos One, 2019
Structural implications of hERG K+ channel block by a high-affinity minimally structured blocker.
Helliwell MV et al.
The Journal of Biological Chemistry, 2018
Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.
Zhang Y et al.
Biochemical Pharmacology, 2016
Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide.
Melgari D et al.
Journal of Molecular and Cellular Cardiology, 2015
The Link between Inactivation and High-Affinity Block of hERG1 Channels.
Wu W et al.
Molecular Pharmacology, 2015
Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Du C et al.
Journal of Molecular and Cellular Cardiology, 2014
Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block.
Dempsey CE et al.
Journal of Chemical Information and Modeling, 2014
Current pharmacogenomic studies on hERG potassium channels.
He FZ et al.
Trends in Molecular Medicine, 2013
Molecular determinants of hERG potassium channel inhibition by disopyramide.
El Harchi A et al.
Journal of Molecular and Cellular Cardiology, 2012
Molecular coupling in the human ether-a-go-go-related gene-1 (hERG1) K+ channel inactivation pathway.
Ferrer T et al.
The Journal of Biological Chemistry, 2011
Molecular determinants for activation of human ether-à-go-go-related gene 1 potassium channels by 3-nitro-n-(4-phenoxyphenyl) benzamide.
Garg V et al.
Molecular Pharmacology, 2011
Blockade of hERG K(+) channel by antimalarial drug, primaquine.
Kim KS et al.
Archives of Pharmacal Research, 2010
Extracellular K+ is a prerequisite for the function and plasma membrane stability of HERG channels.
Massaeli H et al.
Circulation Research, 2010
Stereoselective Inhibition of the hERG1 Potassium Channel.
Grilo LS et al.
Frontiers in Pharmacology, 2010
Effect of sibutramine HCl on cardiac hERG K+ channel.
Kim KS et al.
Molecular and Cellular Biochemistry, 2009
Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K et al.
Journal of Pharmacological Sciences, 2008
The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-à-go-go-related gene (hERG) potassium channels.
Tang Q et al.
British Journal of Pharmacology, 2008
Probing the binding sites and mechanisms of action of two human ether-a-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243).
Xu X et al.
Molecular Pharmacology, 2008
Drug block of the hERG potassium channel: insight from modeling.
Stansfeld PJ et al.
Proteins, 2007
Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
Schwoerer AP et al.
Anesthesiology, 2007
Structural requirements of human ether-a-go-go-related gene channels for block by bupivacaine.
Siebrands CC et al.
Anesthesiology, 2007
Na+ permeation and block of hERG potassium channels.
Gang H et al.
The Journal of General Physiology, 2006
Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
Guo J et al.
The Journal of Pharmacology and Experimental Therapeutics, 2006
Molecular determinants of HERG channel block.
Kamiya K et al.
Molecular Pharmacology, 2006
Molecular mechanisms for drug interactions with hERG that cause long QT syndrome.
Stansfeld PJ et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ et al.
Molecular Pharmacology, 2004
Structural determinants of HERG channel block by clofilium and ibutilide.
Perry M et al.
Molecular Pharmacology, 2004
Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
Ficker E et al.
Molecular Pharmacology, 2001
HERG K+ channels: friend and foe.
Vandenberg JI et al.
Trends in Pharmacological Sciences, 2001
Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant.
Hosaka Y et al.
Channels (austin, Tex.), 0